Published in Mod Pathol on July 31, 2015
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. Trends Endocrinol Metab (2016) 0.76
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Cancer genome landscapes. Science (2013) 25.33
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol (2006) 6.16
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg (1999) 5.58
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin (2012) 4.13
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg (2004) 3.90
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn (2008) 2.30
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat (2002) 1.91
Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res (2012) 1.57
Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res (2002) 1.39
Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res (2001) 1.20
Defective DNA mismatch repair in long-term (> or =3 years) survivors with pancreatic cancer. Pancreatology (2005) 1.16
DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist (2011) 1.02
DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol (2014) 0.87
Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr) (2012) 0.86
Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One (2012) 0.81
Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. J Clin Pathol (2015) 0.77